Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| Top generic companies : new report |
 |
 |
 |
|
The Top 10 Generic Pharmaceutical Companies: Positioning, performance and SWOT analyses Item description ‘The Top 10 Generic Pharmaceutical Companies’ is a new report published by Business Insights that analyzes the size, structure and competitive landscape of the global generics market. The global generics market grew at a faster pace than the global pharma market in 2007, with a CAGR of 16.4% during 2004–2007. Regular patent expirations of blockbuster drugs are the primary growth driver of the industry. Rising healthcare expenditure has also contributed to industry expansion, with governments coming under growing pressure to provide low cost alternatives to branded drugs. However, the generics market is changing due to the threat from authorized generics, competition from players in emerging countries and increasing consolidation. Teva’s acquisition of Barr Pharmaceuticals is the latest example of companies attempting to improve their market strength and geographical reach via divestments and acquisitions. ‘ Some key findings from this report... • The global generics market reached $90.7m in 2007, representing a three-year CAGR of 12.1%. Sales of generic drugs are expected to increase by 14–15% in 2008, as compared with branded pharmaceutical growth of 6–7%. Much of this growth will be driven by the introduction of pro-generic reforms to major markets. • The top 10 generics companies accounted for 28.5% of the global market in 2007. Many leading players are actively updating their product portfolios, seeking growth opportunities in emerging markets, pursuing cost optimization and investing in R&D capabilities. • The US attained generics sales worth $25.4m in 2007, accounting for 26.3% of global market. However, the generics markets of EU countries have a higher growth rate than the US, and accounted for 14.2% of the global sales in 2007. • Generics companies are currently facing a number of major challenges including continued pricing pressure, authorized generics, a lack of patient awareness and distrust among healthcare prescribers. • The nervous system (NS) and cardiovascular system (CVS) were the largest generics therapy areas among the top 10 companies in this report, with a 2007 market share of 31% and 28% respectively. Key issues examined in this report... • Growing presence of branded companies. Branded Pharma companies are increasingly involved in generics production to win back revenues that would otherwise be lost due to patent expiry. After launching their own authorized generics, branded companies are able to delay and inhibit the entry of pure generic players by undercutting price and market share during the exclusivity period. • Rising pressure on pricing. The long term sustainability of generic pharmaceutical companies is coming under threat after government initiatives to promote low cost generics have contributed to product devaluation and reduced profit margins. • Increased consolidation. Generic manufacturers are consolidating in order to compete with rising numbers of specialty pharma companies who possess greater scale and R&D capabilities. The regulatory framework for authorized generics also provides easy market access for specialty developers, forcing pure generic players to consolidate in order to achieve greater vertical integration, scale and R&D skills. Table of Contents Executive Summary Industry overview Novartis (Sandoz) Teva Mylan Ratiopharm Apotex Pfizer (Greenstone) Sanofi-Aventis (Winthrop) Watson Bayer Stada Top trends in the industry 43 Changing paradigms towards emerging markets 43 The generics manufacturing base is shifting to low cost hubs 45 Growing legislative support for 'follow-on biologics' 46 Increasing participation of branded Pharma companies in generics industry 47 Consolidation 49 Top ten generic companies 50 Global ranking 50 US/5EU consolidated 50 Therapeutic focus of the top 10 51 Key marketed products of the top 10 53 Geographic focus of the top 10 54 US ranking 54 EU ranking 55 Chapter 3 Novartis (Sandoz) 58 Summary 58 Business description 59 Geographic focus 60 Marketed products 61 Major therapeutic focus 62 Growth strategies 63 Focus on difficult-to-make and biosimilar generics 63 Acquisitions and divestments 64 SWOT analysis 65 Strengths 66 Size and leading generics position 66 Dynamic launches 66 Weaknesses 67 Development setbacks 67 Opportunities 67 Strong pipeline 67 Threats 68 Legal proceedings 68 Chapter 4 Teva 70 Summary 70 Business description 71 Geographic focus 72 Marketed products 73 Major therapeutic focus 74 Growth strategies 76 Acquisitions and divestments 76 SWOT analysis 77 Strengths 78 Leading generics market position 78 Global infrastructure 78 Weaknesses 79 Distribution model 79 Opportunities 79 Focus on hospitals and institutional channels 80 Threats 80 Failure to obtain market exclusivity in the US 80 Chapter 5 Mylan 84 Summary 84 Business description 85 Geographic focus 86 Marketed products 87 Major therapeutic focus 88 Growth strategies 89 Acquisitions and divestments 90 SWOT analysis 91 Strengths 91 Leading market position in Asia Pacific 91 Growth through strategic acquisitions 92 Weaknesses 92 Dependence on a few key products 92 Opportunities 93 Growing generics demand 93 Threats 93 Merck Generics litigations 93 Chapter 6 Ratiopharm 96 Summary 96 Business description 97 Geographic focus 97 Marketed products 99 Major therapeutic focus 99 Growth strategies 100 Focus on biosimilars 100 Acquisitions and divestments 101 SWOT analysis 102 Strengths 102 Leading position in Germany 102 Weaknesses 103 Dependence on European market 103 Opportunities 103 Biosimilar filgrastim 103 Launch of generic Plavix 103 Threats 104 Competition in German generics market 104 Chapter 7 Apotex 106 |
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis